9 Facts About Testosterone Therapy for Women in Menopause That Most Doctors Don't Explain
The libido piece is what finally made me look into testosterone — but what surprised me was how much it connected to the fatigue and the flat feeling I'd been writing off as just 'getting older.' Finding out there was a name for that, and a real physiological reason, felt like someone had finally turned the lights on.
Learn more about Rose →Women Make Testosterone Their Entire Adult Lives — and Lose It Gradually Before Menopause Even Arrives
Testosterone in women is produced by the ovaries and adrenal glands, and peak levels typically occur in the mid-twenties before declining slowly and steadily across the following decades. By the time a woman reaches her mid-forties, she may already have roughly half the testosterone she had at her peak — meaning low-testosterone symptoms can begin well before periods stop. This gradual decline is why symptoms like reduced libido, fatigue, and loss of motivation are so easy to misattribute to stress, aging, or depression rather than hormonal change.
There Is No Approved Female Testosterone Product in Most Countries — But That Does Not Mean It Is Experimental
In the United States, the United Kingdom, Australia, and most of Europe, there is currently no testosterone product specifically licensed for women, which creates a significant prescribing gap rooted in regulatory history rather than lack of evidence. The 2019 Global Consensus Statement on the use of testosterone therapy for women, endorsed by major menopause societies worldwide, concluded that there is Level 1 evidence supporting testosterone therapy for hypoactive sexual desire disorder (HSDD) in postmenopausal women. Clinicians who prescribe testosterone for women are operating within an evidence-supported framework using off-label or compounded formulations — a common and accepted medical practice when evidence exists but licensing has not caught up.
Low Sexual Desire Is the Best-Evidenced Indication — But It Is Far From the Only Symptom Testosterone Addresses
The strongest and most consistent clinical evidence for testosterone therapy in women relates to hypoactive sexual desire disorder — a persistent, distressing loss of sexual interest that is not explained by relationship issues, medication side effects, or another medical condition. However, women and clinicians also report meaningful improvements in energy levels, cognitive sharpness, mood stability, and muscle maintenance, particularly when testosterone is added to an existing estrogen regimen. These additional benefits are supported by observational data and smaller trials rather than large randomised controlled trials, so they carry a lower evidence grade — but they are real reported outcomes worth discussing with a prescriber.
The Dose Used for Women Is Approximately One-Tenth of a Male Therapeutic Dose
One of the most common reasons women hesitate to consider testosterone therapy is fear of masculinising side effects — voice changes, facial hair, clitoral enlargement, or aggressive mood shifts. These concerns are legitimate but largely dose-dependent: the testosterone levels targeted in female therapy are calibrated to restore levels to the upper end of the normal female physiological range, not to approach male levels. When prescribed and monitored appropriately, the risk of androgenic side effects is low, and most side effects that do occur — such as mild acne or increased body hair at the application site — are reversible upon dose reduction or discontinuation.
Bloodwork Before and During Therapy Is Not Optional — It Is How Safety Is Maintained
Baseline testosterone levels should be measured before starting therapy, both to confirm that a deficiency is genuinely present and to establish a personal reference point for monitoring. During treatment, total testosterone and free testosterone (or calculated free androgen index) should be checked at three to six months and then annually, with the goal of keeping levels within the normal female physiological range rather than chasing a number that feels good symptomatically. A prescriber who is not monitoring levels periodically is not providing adequate care, and women should feel empowered to ask for these tests by name.
Transdermal Delivery Is Strongly Preferred Over Oral Testosterone for Women
Oral testosterone undergoes first-pass metabolism in the liver, which significantly alters its hormonal profile, raises LDL cholesterol, and makes dosing unpredictable — making it a poor choice for women compared to transdermal options. Transdermal testosterone, applied as a gel, cream, or in some countries a patch, delivers the hormone directly into the bloodstream at a more stable and physiologically appropriate rate. Most clinical guidelines for women's testosterone therapy specifically recommend the transdermal route, and this is the approach reflected in the 2019 Global Consensus Position Statement.
Current Evidence Does Not Show Increased Breast Cancer Risk at Physiological Female Doses
Breast cancer risk is the question most women ask first, and the honest answer based on current evidence is that physiological testosterone therapy in women does not appear to increase breast cancer risk — and some observational data has even suggested a potential protective association, though this has not been confirmed in large randomised trials. The 2019 Global Consensus Statement explicitly noted that there is no evidence of increased risk at doses that maintain testosterone within normal female ranges. Women with a personal history of hormone-sensitive breast cancer should have a thorough discussion with an oncologist before starting any hormonal therapy, as this population was excluded from most studies.
Testosterone and Estrogen Often Work Better Together Than Either Does Alone
Many of the clinical trials showing benefit from testosterone therapy for libido, mood, and energy were conducted in women who were also taking estrogen, which means the results cannot always be cleanly separated from the estrogen effect. Estrogen receptors in the brain and genital tissue require adequate estrogen to function properly — without it, testosterone may have a ceiling on how much it can help, particularly for sexual comfort and arousal. Women in early perimenopause with relatively intact estrogen levels may respond differently than postmenopausal women on no estrogen, and prescribers should consider the full hormonal picture rather than treating testosterone in isolation.
Realistic Expectations Matter: Testosterone Is Not a Libido Switch or an Instant Energy Fix
Women starting testosterone therapy should know that response is gradual — most clinical trials measure outcomes at twelve weeks or longer, and meaningful changes in desire, energy, or mood typically emerge over three to six months rather than days or weeks. Testosterone addresses the physiological component of low desire and fatigue, but it does not override relationship dynamics, chronic sleep deprivation, untreated depression, or unmanaged stress — all of which need to be part of the wider conversation. Setting realistic expectations upfront protects against early abandonment of a therapy that simply needed more time, and against disappointment when testosterone turns out to be one piece of a larger puzzle rather than the whole answer.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.